Related references
Note: Only part of the references are listed.Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management
Morie A. Gertz
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis
Shaji K. Kumar et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score
Shaji K. Kumar et al.
MAYO CLINIC PROCEEDINGS (2011)
Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features
Shaji Kumar et al.
BLOOD (2010)
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report
Morie A. Gertz et al.
LEUKEMIA & LYMPHOMA (2010)
Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis
Morie Gertz et al.
LEUKEMIA & LYMPHOMA (2008)
Long-term outcome-of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation
Vaishali Sanchorawala et al.
BLOOD (2007)
Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL)
M. A. Gertz et al.
BONE MARROW TRANSPLANTATION (2007)
Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response
Morie A. Gertz et al.
HAEMATOLOGICA (2007)
High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: A Center for International Blood and Marrow Transplant Research study
David H. Vesole et al.
MAYO CLINIC PROCEEDINGS (2006)
Clinical aspects of systemic amyloid diseases
L Obici et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2005)
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
MA Gertz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2005)
High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study
M Skinner et al.
ANNALS OF INTERNAL MEDICINE (2004)
Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation
DC Seldin et al.
BLOOD (2004)
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
A Dispenzieri et al.
BLOOD (2004)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate
MA Gertz et al.
BONE MARROW TRANSPLANTATION (2004)
Stem cell transplantation for the management of primary systemic amyloidosis
MA Gertz et al.
AMERICAN JOURNAL OF MEDICINE (2002)
An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis
V Sanchorawala et al.
BONE MARROW TRANSPLANTATION (2001)
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
